In addition, treatment with a HDAC inhibitor, namely suberoylanilide hydroxamic acid, has been substantiated to retard the proliferative and metastatic properties of GBC cells and tumor formation in GBC xenograft models [24]. Here, HDAC9 is linked to neoplasm.